Noticias de ATHE_US

Noticias del mercado

Últimas noticias sobre ATHE_US — 39 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATHE_US ✕ 39 resultados
17/04/2026 ATHE_US — Stock Titan
Alterity brings in ex-Lilly, Teva executive ahead of Phase 3 push
16/04/2026 ATHE_US — The Manila Times ES ← EN
Alterity Therapeutics anuncia una presentación oral de última hora en la reunión anual de la Academia Estadounidense de Neurología
16/04/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
16/04/2026 ATHE_US — Stock Titan
Late-breaker ATH434 MSA results at AAN 2026 for Alterity (ATHE)
16/04/2026 ATHE_US — Stock Titan
Rare disease drug data lands late-breaker slot at neurology meeting
15/04/2026 ATHE_US — GlobeNewswire
Alterity Therapeutics to Host Virtual KOL Event to Share
15/04/2026 ATHE_US — Stock Titan
No approved treatment for Multiple System Atrophy: Alterity webcast April 28
11/04/2026 ATHE_US — Stock Titan
ATHE SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms
30/03/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) gets positive FDA feedback on ATH434 Phase 3 MSA program
30/03/2026 ATHE_US — Stock Titan
FDA feedback moves Alterity's atrophy drug toward Phase 3
30/03/2026 ATHE_US — Bitget
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30/03/2026 ATHE_US — GlobeNewswire ES ← EN
Alterity Therapeutics recibe comentarios positivos de la FDA luego de la reunión tipo C sobre el programa de fase 3 ATH434
26/03/2026 ATHE_US — TipRanks
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
09/03/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) preps Phase 3 and joins Bell Potter summit
04/03/2026 ATHE_US — Stock Titan
MSA trial expert Daniel Claassen to guide Alterity's ATH434 Phase 3
04/03/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) taps Dr. Daniel Claassen as Chief Medical Advisor
02/03/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
02/03/2026 ATHE_US — Stock Titan
Rare brain disease with no approved treatment spurs new Alterity drug push
30/01/2026 ATHE_US — Stock Titan
Experimental MSA drug ATH434 inches toward Phase 3 on stronger data

Página 2 de 2

keyboard_arrow_up